A talented, experienced team has come together to work together again. Amalgent quickly recognized the unmet need in acute pain, and the opportunity to develop new pain medications.
Chief Executive Officer
Chris Kelly is a serial entrepreneur, and leads growth companies by combining corporate development, finance, and global operations expertise.
He has started several companies and has been brought in by the boards of startups to drive growth. Chris co-founded Xlibris Corporation, the first self-publishing technology company which was sold to Penguin Random House. As CEO he led Ribonomics, a biotechnology company that was sold to MBL International. He co-founded Galaxy Diagnostics; as CEO, he led Galaxy through two rounds of seed-stage funding.
Chris is a veteran of 60 acquisitions, venture investments and strategic transactions across four continents, and industries including drug development, materials sciences, biotechnology, business services and information technology.
Co-founder and Chief Scientific Officer
Malcolm Meyn is the Chief Scientific Officer of Amalgent Therapeutics. He co-founded the company in 2020 with the goal of developing and commercializing the opioid adjuvant technology invented at East Carolina University. Malcolm began his career as an academic scientist researching the complex systems that regulate how cells and organisms respond to chemical signals. In 2011, he took his skills to industry and began to focus on developing biologic and small drug therapeutics. At Amalgent Therapeutics, Malcolm oversees all research and development programs, supports business development, assists in strategic decision making, and sits on the Board of Directors.
Vice President, Corporate Development
Mickey Ramchandani has been successfully building teams and businesses in pharmaceutical, diagnostic and medtech industries for more than 25 years. Prior to joining Amalgent in 2021, Mickey was Founder and CEO of Global Lyme Diagnostics (GLD) where he successfully raised an oversubscribed Serie A/B financing. Prior to GLD, Mickey led all non-US commercialization for TranS1 as VP of Corporate Development & General Manager.
Earlier in his career, he held roles in licensing and business development at Kowa and Baxter International. Mickey began his career in drug discovery research at Pfizer, Inc.
Co-founder and non-executive Chair
Sam is Founder and CEO of Grant Engine, a technology consulting firm focused on providing grant writing and other advisory services to university-based inventors and entrepreneurs. He identified the opportunity at Amalgent with Malcolm, and began the Company in 2020. Sam is an active angel investor and member of RTP Capital and Carolina Angel Network.